损坏的FADD/BID信号传递调解了多发性骨髓瘤中免疫治疗的交叉耐药性
Umair Munawar1, Xiang Zhou1, Sabrina Prommersberger1
1Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Communications biology
|December 22, 2023
概括
死亡受体信号受损是多发性骨髓瘤 (MM) 中对T细胞免疫疗法的新抵抗机制. 这种涉及FADD/BID的途径对于治疗反应至关重要,为MM提供了新的治疗点.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 多发性骨髓瘤 (MM) 治疗正在向免疫疗法发展,包括单克隆抗体和CAR T细胞,改善反应率.
- 尽管取得了进展,但患者复发仍然是一个挑战,抵抗机制尚不清楚.
- 已知死亡受体信号受损会导致白血病中CAR-T细胞耐药性,但在MM免疫疗法中尚未探索.
研究的目的:
- 确定多发性骨髓瘤 (MM) 中T细胞介导免疫疗法的新型耐药性机制.
- 调查死亡受体信号在MM对新型免疫疗法的耐药性中的作用.
- 探索FADD/BID轴作为MM的潜在治疗目标.
主要方法:
- 分析多发性骨髓瘤 (MM) 细胞系中的抵抗机制.
- 在体外测试对新型免疫疗法与传统疗法的敏感性.
- 临床案例研究以确认FADD/BID轴的作用.
主要成果:
- 死亡受体信号受损被确定为MM中T细胞介导免疫疗法的新型耐药机制.
- 这种耐药性似乎是新型免疫疗法的特征,对常规治疗的敏感性保持在体外.
- 一个临床案例证实了FADD/BID轴对于对新型免疫疗法的反应至关重要.
结论:
- 死亡受体信号受损是多发性骨髓瘤中对T细胞免疫疗法耐药性的关键机制.
- FADD/BID通路对于对新型MM免疫疗法的有效反应至关重要.
- 准死亡受体通路可能会克服耐药性,并改善MM患者的治疗结果.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
The Extrinsic Apoptotic Pathway
6.4K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.4K
Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529


